Form 8-K - Current report:
SEC Accession No. 0001493152-24-047613
Filing Date
2024-11-25
Accepted
2024-11-25 16:13:19
Documents
15
Period of Report
2024-11-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 50313
2 ex2-1.htm EX-2.1 19941
  Complete submission text file 0001493152-24-047613.txt   251216

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE evfm-20241119.xsd EX-101.SCH 3009
4 XBRL LABEL FILE evfm-20241119_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE evfm-20241119_pre.xml EX-101.PRE 24161
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3587
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

EIN.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 241496059
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)